Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in Europe
- Registration Number
- NCT01890993
- Lead Sponsor
- Novo Nordisk A/S
- Brief Summary
This study is conducted in Europe. The aim of this study is to demonstrate the clinical effectiveness and safety of liraglutide and dipeptidyl peptidase-4 (DPP-4) inhibitor therapy in routine primary care in Europe.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 952
Inclusion Criteria
- Patients treated with liraglutide or DPP-4 inhibitors, according to license in respective participating country with data available for 12 (+/- 2) months
Exclusion Criteria
- Patients treated with liraglutide or DPP-4 inhibitors, outside of license in respective participating country
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Liraglutide liraglutide - DPP-4 liraglutide -
- Primary Outcome Measures
Name Time Method Change in HbA1c (glycosylated haemoglobin) Baseline (anytime within 3 months before therapy initiation), month 12 (+/-2)
- Secondary Outcome Measures
Name Time Method Change in systolic blood pressure Baseline (anytime within 3 months before therapy initiation), month 12 (+/-2) Change in body weight Baseline (anytime within 3 months before therapy initiation), month 12 (+/-2)
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie liraglutide's efficacy in type 2 diabetes compared to DPP-4 inhibitors?
How does liraglutide compare to DPP-4 inhibitors in managing HbA1c and weight loss in primary care settings?
Which biomarkers correlate with improved glycemic control in liraglutide-treated type 2 diabetes patients?
What are the long-term adverse event profiles of liraglutide versus DPP-4 inhibitors in primary care populations?
How do GLP-1 receptor agonists like liraglutide differ from DPP-4 inhibitors in cardiovascular outcomes for type 2 diabetes?